middle.news
Radiopharm advances RAD101 toward pivotal brain imaging trial
4:34pm on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Radiopharm advances RAD101 toward pivotal brain imaging trial
4:34pm on Friday 30th of October, 2026 AEDT
Key Points
RAD101 Phase 3 trial expected to begin in the first quarter of 2027
Phase 2b RAD101 data showed 93% concordance with MRI across evaluable lesions
RAD301 Phase 1 data supported further development in pancreatic cancer
A$7.46 million quarter-end cash against A$10.69 million operating outflows
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE